These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 19887545

  • 1. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H.
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [Abstract] [Full Text] [Related]

  • 2. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
    Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H.
    Cancer Biol Ther; 2010 Apr 01; 9(7):514-22. PubMed ID: 20107315
    [Abstract] [Full Text] [Related]

  • 3. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
    Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M.
    Clin Cancer Res; 2011 May 01; 17(9):2799-806. PubMed ID: 21389100
    [Abstract] [Full Text] [Related]

  • 4. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
    Leijen S, Beijnen JH, Schellens JH.
    Curr Clin Pharmacol; 2010 Aug 01; 5(3):186-91. PubMed ID: 20406171
    [Abstract] [Full Text] [Related]

  • 5. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.
    Mol Cancer Ther; 2013 Aug 01; 12(8):1442-52. PubMed ID: 23699655
    [Abstract] [Full Text] [Related]

  • 6. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.
    Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE.
    Clin Cancer Res; 2011 Sep 01; 17(17):5638-48. PubMed ID: 21799033
    [Abstract] [Full Text] [Related]

  • 7. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
    Mizuarai S, Yamanaka K, Itadani H, Arai T, Nishibata T, Hirai H, Kotani H.
    Mol Cancer; 2009 Jun 08; 8():34. PubMed ID: 19500427
    [Abstract] [Full Text] [Related]

  • 8. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
    Davies KD, Cable PL, Garrus JE, Sullivan FX, von Carlowitz I, Huerou YL, Wallace E, Woessner RD, Gross S.
    Cancer Biol Ther; 2011 Nov 01; 12(9):788-96. PubMed ID: 21892012
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ, Schellens JHM.
    Clin Cancer Res; 2017 Aug 15; 23(16):4540-4544. PubMed ID: 28442503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
    Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.
    Mol Cancer Ther; 2015 Feb 15; 14(2):608-19. PubMed ID: 25504633
    [Abstract] [Full Text] [Related]

  • 14. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.
    Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A.
    Cancer Biol Ther; 2014 Apr 15; 15(4):380-8. PubMed ID: 24365782
    [Abstract] [Full Text] [Related]

  • 15. Cytokinetic effects of Wee1 disruption in pancreatic cancer.
    Chang Q, Chandrashekhar M, Ketela T, Fedyshyn Y, Moffat J, Hedley D.
    Cell Cycle; 2016 Apr 15; 15(4):593-604. PubMed ID: 26890070
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antitumor effect of WEE1 blockade as monotherapy or in combination with cisplatin in urothelial cancer.
    Murakami K, Kita Y, Sakatani T, Hamada A, Mizuno K, Nakamura K, Takada H, Matsumoto K, Sano T, Goto T, Akamatsu S, Saito R, Tsuruyama T, Ogawa O, Kobayashi T.
    Cancer Sci; 2021 Sep 15; 112(9):3669-3681. PubMed ID: 34212455
    [Abstract] [Full Text] [Related]

  • 19. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
    Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S.
    Leukemia; 2015 Apr 15; 29(4):807-18. PubMed ID: 25283841
    [Abstract] [Full Text] [Related]

  • 20. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L.
    J Exp Clin Cancer Res; 2018 Jun 28; 37(1):129. PubMed ID: 29954437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.